- Home
- PXLW vs CRVO Comparison
PXLW vs CRVO Comparison
Compare PXLW & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PXLW | CRVO |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 35.9M |
| IPO Year | 2000 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PXLW | CRVO |
|---|---|---|
| Price | $6.93 | $3.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $14.33 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 104.9K | 50.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $693,000.00 | ★ $4,006,510.00 |
| Revenue This Year | $47.19 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $2.82 |
| 52 Week High | $15.42 | $13.13 |
Technical Indicators
Market Signals| Indicator | PXLW | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 64.55 | 35.39 |
| Support Level | $6.80 | N/A |
| Resistance Level | $7.03 | $4.27 |
| Average True Range (ATR) | 0.49 | 0.26 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 74.46 | 22.80 |
Price Performance
Historical ComparisonAbout PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.